PMI invests $150m in Philippine no-burn tobacco production

Sep.30.2022
PMI invests $150m in Philippine no-burn tobacco production
Philip Morris invests 8.8 billion Philippine pesos to produce smoke-free tobacco pods in the Philippines, with estimated commercial production in 2023.

Philip Morris International will invest PHP 8.8 billion ($150 million) to start producing tobacco pods for smokeless heating in the Philippines, with the aim of moving away from traditional cigarettes.


Commercial production is expected to begin in the fourth quarter of 2023 in a local joint venture between the US Tobacco Group and the billionaire Lucio Tan's corporate group, LT Group, under the name PMFTC.


This will mark PMI's first production of heated tobacco sticks in the Philippines. PMI announced at a press conference on Wednesday that production will take place at an existing cigarette factory in Batangas province on the island of Luzon.


PMI's handheld IQOS device heats tobacco without burning it, producing vapor but not smoke or ash. PMFTC brought IQOS to the Philippines in 2020.


PMI has announced that this investment will create 220 job openings and utilize tobacco plants grown in the Philippines.


It is estimated that over 20% of adults in the Philippines smoke, which is a higher percentage compared to Japan.


Statement:


This article is compiled from third-party information for the purpose of industry discussion and learning.


This article does not reflect the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article is compiled solely for industry-based communication and research purposes.


Due to limitations in translation ability, the translated article may not accurately express the original content. Please refer to the original article for accuracy.


In regards to any domestic, Hong Kong, Macau, Taiwan, or foreign statements and positions, 2FIRSTS is fully aligned with the Chinese government.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
BAT’s Vuse Ultra listed as GOOD DESIGN Awards winner; features app connectivity and adjustable intensity
BAT’s Vuse Ultra listed as GOOD DESIGN Awards winner; features app connectivity and adjustable intensity
British American Tobacco’s (BAT) Vuse Ultra vaping product has been listed among winners on the U.S. GOOD DESIGN Awards website, in the “Personal Experience” category, according to the project page. The page identifies the award year as 2025 and names BAT (London) as both the entrant and the manufacturer.
Jan.20 by 2FIRSTS.ai
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
The vaping brand OXBAR has recently listed its open-system, refillable pod device OX35K on its official website. The product features a “2ml built-in pod + two 10ml external refill bottles” e-liquid supply structure and supports top refilling, with a claimed puff count of up to 35,000. It is equipped with a 1000mAh built-in battery and offers dual power modes—BOOST and ECO—positioning the device to balance high-puff performance with an open-system form factor.
Jan.13 by 2FIRSTS.ai
Uruguay Lawmaker Proposes Ban on Smoking and Vaping in Playgrounds and Bus Stops
Uruguay Lawmaker Proposes Ban on Smoking and Vaping in Playgrounds and Bus Stops
A bill introduced by Uruguayan lawmaker Álvaro Dastugue proposes banning smoking and vaping in public spaces that include children’s play areas, as well as at bus stops and nearby waiting zones. The draft legislation aims to reduce involuntary exposure to smoke and aerosols from tobacco, marijuana and electronic vaping devices.
Dec.24 by 2FIRSTS.ai
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
Product | Claiming “U.S.-Made E-Liquid” and “80,000 Puffs,” VOOPOO Launches NAVI×Cyph 80K
VOOPOO’s website shows the company has introduced the NAVI×Cyph Kit 80K, an open-system, refillable vaping kit claimed to deliver up to 80,000 puffs. The device features a 1,500mAh battery with USB Type-C charging and comes in 12 flavors. A promotional image posted on VOOPOO’s official Instagram account includes the phrase “E-LIQUID BUILT IN THE USA.”
Feb.10 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11